 
STX-100 Phase 2 Trial in Idiopathic Pulmonary Fibrosis Now Recruiting Patients
GO >
MORE NEWS >
Download our Company
Fact Sheet
DOWNLOAD (PDF) >
Follow Stromedix on Twitter
GO >
|
|
Stromedix, Inc.
One Canal Park, Suite 1120
Cambridge MA 02141
tel 617.674.8400
fax 617.674.8390
info@stromedix.com |
|
 
STX-100 is Stromedix's first clinical candidate and is being developed for the treatment of idiopathic pulmonary fibrosis.
 |
Humanized monoclonal antibody to integrin αvβ6 |
|
Completed phase 1 clinical testing |
|
Provides localized, injury-specific inhibition of TGF-β activation
|
|
Significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease |
|
Broad therapeutic utility in chronic organ failure, acute organ failure and cancer |
|
Phase 2 clinical trial for patients with idiopathic pulmonary fibrosis now open. More information at ClinicalTrials.gov. |
|
